Pancreatic Cancer Research

ResearcherThe University of TokyoActive in the last 2 years

Kiyoshi Hasegawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8734-740X; OpenAlex author ID A5059152283. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 16

  1. Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy. Last author DOI 10.1016/j.hpb.2025.12.021↗
  2. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  3. Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? Last author DOI 10.1245/s10434-025-18511-2↗
  4. Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance:… Co-author DOI 10.1136/gutjnl-2024-333259↗
  5. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  6. The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection. Last author DOI 10.1097/mpa.0000000000002291↗
  7. Bioinformatics-based screening of key genes associated with gemcitabine resistance in advanced pancreatic ductal adenocarcinoma. First author DOI 10.21037/tcr-2024-2374↗
  8. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  9. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  10. Radical Antegrade Modular Pancreatosplenectomy for Left-Sided Pancreatic Ductal Adenocarcinoma May Reduce the Local Recurrence Rate. Last author DOI 10.1159/000524927↗
  11. Fluorescence Imaging Using Enzyme-Activatable Probes for Real-Time Identification of Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.714527↗
  12. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  13. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2017.12.083↗
  14. Predictors of Postoperative Non-Chylous Massive Discharge after Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000479341↗
  15. Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer. Co-author DOI 10.1016/j.jcyt.2017.01.002↗
  16. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Co-author DOI 10.18632/oncotarget.11129↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuhiro Fujishiro · 7 shared papers, 2022–2026 · strength 1.28
  2. Yousuke Nakai · 8 shared papers, 2016–2026 · strength 1.14
  3. Tatsunori Suzuki · 6 shared papers, 2022–2026 · strength 1.08
  4. Satoru Abe · 4 shared papers, 2024–2026 · strength 0.92
  5. Tsuyoshi Hamada · 5 shared papers, 2022–2026 · strength 0.83
  6. Yusuke Kazami · 3 shared papers, 2026 · strength 0.75
  7. Sho Kiritani · 3 shared papers, 2022–2026 · strength 0.73
  8. Yosuke Inoue · 4 shared papers, 2022–2026 · strength 0.63
  9. Manabu Takamatsu · 4 shared papers, 2022–2026 · strength 0.63
  10. Tsuyoshi Takeda · 4 shared papers, 2022–2026 · strength 0.63
  11. Minoru Kitago · 4 shared papers, 2022–2026 · strength 0.63
  12. Yohei Masugi · 4 shared papers, 2022–2026 · strength 0.63
  13. Yu Takahashi · 4 shared papers, 2022–2026 · strength 0.63
  14. Sho Uemura · 4 shared papers, 2022–2026 · strength 0.63
  15. Naoki Sasahira · 4 shared papers, 2022–2026 · strength 0.63
  16. Takeshi Takamoto · 2 shared papers, 2026 · strength 0.55
  17. Kazunaga Ishigaki · 3 shared papers, 2018–2026 · strength 0.52
  18. Naminatsu Takahara · 3 shared papers, 2018–2026 · strength 0.52
  19. Kazuhiko Koike · 4 shared papers, 2016–2024 · strength 0.42
  20. Yosuke Uematsu · 2 shared papers, 2025–2026 · strength 0.38
  21. Kaifeng Hu · 1 shared paper, 2024 · strength 0.36
  22. Guozhi Zhou · 1 shared paper, 2024 · strength 0.36
  23. Norihiro Kokudo · 5 shared papers, 2016–2018 · strength 0.36
  24. Takeaki Ishizawa · 2 shared papers, 2021–2022 · strength 0.31
  25. Hideaki Ijichi · 3 shared papers, 2016–2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.